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Introduction
The AIDS epidemic is well into its second decade and up to date has claimed
13.9 million lives. Human immunodeficiency virus (HIV) is the causative agent of
AIDS and according to the December 1998 estimates of UNAIDS (United Nations
AIDS Programme) 32.4 million people are living with HIV/AIDS worldwide. The
main routes of HIV transmission are sexual, from mother to child or by intravenous
drug use. At the beginning of the epidemics blood and blood products played an
important role, but testing of blood donors and control of blood products have
successively minimized the risk of becoming infected by this route.
HIV is a retrovirus, a member of the lentivirus subfamily. Lentiviruses occur in
several animal species and cause slow – often fatal – diseases affecting various organ
systems depending on the species and the age of the animal at the time of infection
(reviewed in [1]). In HIV-infected humans, gradual depletion of CD4+ T cells results in
immunodeficiency after several years and leads to the clinical entity of acquired
immunodeficiency syndrome (AIDS). The rate of CD4+ cell depletion is highly
variable in different individuals, from stable CD4 counts in long-term nonprogressors
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(>10 years) to a decline of 15×106 cells/liter/month leading to AIDS in a few years.
Also, infection by HIV type 1 (HIV-1) as known in Central Africa, Europe and the
Americas, leads to immunodeficiency much faster than infection with HIV type 2
(HIV-2) in West Africa [2]. Still today we do not know what exactly determines the
disease progression rate in individual patients. Conceivably, virus-host cell interactions
have a decisive role in this process. Here we shall focus on the biological phenotype of
the virus which has been demonstrated to vary according to the severity of HIV
infection, thus providing a marker for viral virulence.
Biological variation of HIV-1
The original observation some 14 years ago that the rate of HIV-1 replication
and the amounts of virus obtained in primary isolation cultures vary according to the
severity of HIV-1 infection in the patient suggested that we might be looking at viral
determinants of the pathogenic process. This prompted us to further investigate HIV-1
biological phenotype, such as replication rate, cytopathology and cell tropism in tissue
culture, in primary cells and established cell lines. Based on biological phenotype, such
as replication rate, HIV-1 isolates could be divided into two major groups [3–5]. In one
group virus could be isolated within days from peripheral blood mononuclear cells
(PBMC) of HIV-1 infected immunodeficient patients, and was able to induce syncytia
not only in PBMC but also in cell lines. Hence the designation, rapid/high or syncytium
inducing (SI). The other group of viruses was characterized by a prolonged time to
isolation (2–3 weeks), slow replication rate in PBMC, absence of or marginal
cytopathology (small syncytia or cell killing) and inability to infect established T-
lymphoid and monocytoid cell lines. Most primary HIV-1 infections occur with this
latter type of virus, called slow/low or non-syncytium inducing (NSI). Those
individuals that do become infected with rapid/high or SI virus lose CD4 cells at a
faster rate than slow/low or NSI virus infected individuals [6]. Changes in viral
phenotype may also occur within the same infected individual undergoing clinical
progression, and have been shown to involve switch from NSI to SI [7, 8]. Using
syncytium induction in MT-2 cells to test the phenotype of sequential isolates derived
from a cohort of 53 HIV-1 infected homosexual men over a period of 5–8 years, we
found that no change in NSI phenotype was associated with a better prognosis (Table I)
[9]. Taken together, the data from our group and from several others indicate that HIV-
1 biological phenotype is a marker for viral virulence. Recently, these phenotypic traits
could be translated into molecular terms, such as coreceptor usage, opening new doors
in our understanding of HIV-1 pathogenesis.
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Table I
HIV-1 biological phenotype and CD4+ cell decline
MT-2 tropism No. of patients CD4+ counts × 106 cells/liter
End of study Baseline
Neg/Neg 26 327 489
Neg/Pos 20 104 397
Pos/Pos 6 57 308
Table II
Classification of HIV-1 biological phenotypes
Chemokine receptor usage New classification Previous terminology based on
cytopathology in MT-2 cells replication rate in PBMC
CXCR4 X4 SI rapid/high
CCR5 R5 NSI slow/low
/CCR3/CCR2b R3/R2b
CXCR4 and CCR5 R5X4 SI rapid/high
and/or CCR3 R3R5X4 or R3X4
It has long been recognized that HIV-1 uses the CD4 receptor for cell entry [10,
11]. It has also been known that CD4 alone is not enough, since transfection of CD4
into non-human cells did not allow viral entry and infection of cells [12, 13]. By
functional cDNA cloning an HIV-1 entry cofactor has recently been identified as a
member of the seven transmembrane G-protein coupled receptor family [14].
Discovery of the first cofactor, shown to function as coreceptor for HIV-1 isolates able
to infect established cell lines, was soon followed by several others [15–17]. The two
phenotypically different groups of HIV-1, while both using CD4, could be
distinguished by their coreceptor usage, inasmuch rapid/high or SI viruses were shown
to use CXCR4, and slow/low or NSI viruses CCRS [18, 19]. This major pattern was
straightforward and allowed the establishment of a new nomenclature (Table II) [20].
What are these cell surface structures that HIV learned to use as keys to enter
cells? Recent development in the field of immunology has disclosed, in addition to
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traditional cytokines (like interferons and interleukines) the existence of
chemoattractant substances – called chemokines – that serve as mediators in cell-to-cell
signalling (reviewed in [21]). Chemokines belong to a superfamily and show
similarities in their primary structure, characteristically a conservation of 4 cysteines in
a molecule composed of 65–95 amino acids. Depending on whether the first two
cysteines are intercalated by an amino acid or not, chemokines fall into two major
groups, CXC or CC chemokines. From the point of view of HIV-1, SDF-1 (stromal
cell-derived factor-1) [22, 23] is the prototype for CXC chemokines and RANTES
(regulated on activation normal T cell expressed and secreted), MIP-lα and MIP-1β2
(32 represent CC chemokines [24]). While SDF-1 is produced in many different tissues
and apparently has a house keeping function, RANTES, MIP-lα and MIP-1β are
involved in inflammatory processes [25]. Chemokines exert their effect on cells by
binding to specific receptor molecules followed by intracellular signalling. Chemokine
receptors belong to the family of seven transmembrane G-protein coupled receptors,
members of which have been identified as coreceptors for HIV-1. There are at least two
consequences of this coincidence: i) chemokines may inhibit HIV-1 replication [24] by
preferentially binding to the same receptor(s), ii) receptor availability may select for
certain viral variants.
Phenotypic differences correlate with distinct coreceptor usage
To test chemokine receptor usage by primary HIV-1 isolates, human cell lines,
such as the U87 glioma and the HOS osteosarcoma, were engineered to stably express
CD4 and coreceptors [15, 18, 26]. Following HIV-1 infection, the U87.CD4 cell lines
expressing CCR1, CCR2, CCR3, CCR5 or CXCR4 were scored for syncytia and p24
antigen production at day 3–7. GHOST(3) cells expressing the chemokine receptors
CCR3, CCR5 or CXCR4 or the orphan receptors Bonzo or BOB, contain the green
fluorescence protein (GFP) driven by the HIV-2 long terminal repeat. HIV-infected
GHOST(3) cells express GFP and the fluorescence can be observed in a UV
microscope and quantitated by flow cytometry. Using the U87.CD4 cell system we
could show that HIV-1 isolates of different biological phenotype are distinguished by
their ability to use the chemokine receptor CXCR4 for entry into target cells [18, 19].
Slow/low viruses formed syncytia on CCR5-expressing cells only (RS viruses), while
rapid/high viruses used CXCR4 either alone or in combination with CCR5 (X4 or
RSX4 dual tropic, respectively). Syncytium induction by an R5 and R5X4 virus is
illustrated in Figure 1. It has to be pointed out that CXCR4-using viruses could often
use several receptors, not only CCR5 but CCR3 and some even CCR2, suggesting that
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a broader cell tropism might enable the virus to infect many different cell types and this
may conceivably contribute to the increased virulence of these viruses. Moreover, we
found that all HIV-1 isolates are syncytium inducing – provided the target cells carry
the receptor required for infection by the particular virus. The receptor not only has to
be present on the target cell surface but it has to be expressed in a high enough
concentration to trigger syncytium formation. We know today that low CCR5
expression on PBMC allowed slow replication but rarely syncytia formation by viruses
using this receptor (the so-called slow/low or NSI viruses), whereas high
concentrations of CXCR4 in the same cultures allowed fast replication and extensive
syncytia formation of viruses using CXCR4 (rapid/high or SI).
Fig. 1. Syncytium induction by an R5 and R5X4 virus
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Sequential isolates from patients with progressive HIV-1 disease may differ in
coreceptor usage
Changes in HIV-1 phenotype during clinical progression – often measured as
the capacity to induce syncytia in MT-2 cells – have been observed by several groups
over the years. Early work has shown that the change involved a phenotypic switch
from NSI to SI, as a rule, and lead to the suggestion that SI virus is more virulent than
NSI virus [7, 27]. Since we know today that the ability of HIV-1 to infect and induce
syncytia in MT-2 cells is dependent on usage of the CXCR4 coreceptor, the
phenomenon of viral phenotypic evolution could be revisited in terms of evolution of
coreceptor usage. Our results have shown that both in adults and children who acquired
HIV-1 infection from their mother, an R5 virus is present early in infection [19].
Clinical progression and decline in CD4 counts is often accompanied by either a
switch from R5 to X4 or by a broadening of coreceptor usage yielding multitropic
viruses (R5X4 or R3R5X4). In parallel with evolution of coreceptor usage, there is a
change in the virus sensitivity to CC chemokines-mediated inhibition [28]. Replication
of R5 viruses, but not those using CXCR4 (X4 or multitropic viruses), can be inhibited
by RANTES, MIP-lα and often by MIP-1β as well [18]. Evolution to resistance by CC
chemokine mediated inhibition occurs in about half of the AIDS patients, while R5
viruses with apparently preserved sensitivity to inhibition by CC chemokines can be
recovered from the other half [29]. The impact of this change on the pathogenic process
is not well understood. It is an attractive idea that the microenvironment, including
cytokines, chemokines and available target cells, in the different organs of an infected
individual, selects for virus with different biological properties.
Biological variation appears to be an universal property of HIV-1 isolates
across genetic subtypes
Extensive genetic variation of HIV has been well documented (for latest update
see ref. [30]). HIV-1 and HIV-2 show an overall difference of 50% in nucleotide
sequences. A common measure of differences between viruses and groups of viruses is
the divergence between env genes, the most variable of the HIV structural genes.
Envelope homology between HIV-1 and HIV-2 is less than 50%. HIV-1 itself can be
divided into three distantly related groups; the Major (M) and the Outlier (O) groups,
and the newly identified N group of viruses [31]. The M group, which is by far the
most widespread, is further subdivided into distinct “clades” or "envelope sequence
subtypes", differing by approximately 30–35% at the nucleotide and amino acid
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sequence level. The clades are phylogenetic groupings that probably represent a
founder effect, that is, the historical beginnings of HIV-1 epidemics in different groups
of people around the world. Clade determination is a convenient means of tracking the
spread of the virus. env clade B, for example, was initially identified in viral isolates
from Europe and North America. It has now spread to many other parts of the world.
Clade C is the most frequently encountered world wide, mounting to 48% of all HIV-1
infections, while clade A represents 23.5% (UNAIDS 1998 estimates). Emergence of
recombinant viruses composed of sequences from different clades in different parts of
the virus have been described. For example, an A/B recombinant (A in gag and B in
env) is held responsible for the HIV-1 epidemics in the Kaliningrad area of Russia [32].
The immediate question which arises is what impact has HIV genetic variation on the
biology of the virus? Do different clades differ also in virulence? in transmissibility? Is
the emergence of recombinant viruses a continuous threat to produce viruses with
increased virulence and thereby accelerate the epidemics? Initial studies carried out
within the framework of WHO Network involving replication and syncytium induction
in PBMC and cell lines, showed no major differences in biological properties of
subtypes A–E [33, 34]. More recent work not only confirmed that biological variation
is a universal property of HIV-1 isolates across genetic subtypes [35] but showed that
coreceptor usage varies with severity of HIV-1 infection. Like in subtype B infections,
CXCR4-using viruses were frequently recovered from AIDS patients infected with
subtype A, D and E, while individuals in earlier stages of HIV-1 infection yielded
predominantly R5 viruses. However, subtype C appears to be at variance with this
general pattern, in that isolates are R5, regardless of the severity of HIV-1 infection in
the patient (Table III) [36]. Since this is true for subtype C isolates obtained in Sweden
(15 isolates), Ethiopia (0/9) and South Africa (1/9) it cannot simply be the result of a
founder effect in a certain geographic area. The results suggest that subtype-dependent
differences in frequency of usage of certain coreceptors may exist. This opens up the
possibility that genetic subtypes, subtype C in particular, may differ in important
biological properties such as virulence, tissue tropism and transmissibility.
The promiscuous relative: HIV-2
HIV-2 is less pathogenic than HIV-1 and therefore lends itself for studies on
coreceptor usage in relation to pathogenesis. Like HIV-1, a majority (10 out of 11) of
HIV-2 isolates use CCR5. Among AIDS patients two out of seven isolates obtained
used CXCR4 and showed syncytium induction. Similarities between HIV-1 and HIV-2
end here, however, because unlike HIV-1, most HIV-2 isolates use CCR1, CCR2,
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CCR3, BOB and/or perhaps Bonzo as well [37]. Interestingly, nearly all HIV-2 isolates
replicate in MT-2 cells, although they do not induce syncytia. In addition to CXCR4,
MT-2 cells express BOB mRNA and HIV-2 infection most probably occurs by the
orphan receptor BOB. The results indicate that while HIV-1 often evolve to
multitropism in the course of the pathogenic process and multitropism is most often
associated with CXCR4 usage, multitropism is a general property of HIV-2 isolates.
Consequently, multitropism per se cannot be held responsible for differences between
HIV-1 and HIV-2 pathogenesis.
Table III
Coreceptor usage of HIV-1 genetic subtypes A–E and severity of infection
Subtype AIDS No. of isolates Coreceptor usage
CCR5 CXCR4
A – 12 10 2
+ 8 4 4
B – 13 13 0
+ 7 1 6
C – 23 23 0
+ 13 13 0
D – 5 3 2
+ 9 3 6
E – 7 6 1
+ 2 0 2
To further investigate the in vivo relevance of multitropism, we infected PBMC
from individuals homozygous for the deletion in the ccr5 gene (deletion of 32
nucleotides, the so-called ¨ PXWDWLRQ > @ ZLWK  +,9 DQG  +,9 LVRODWHV
Taking extracellular antigen production as evidence for productive infection, only
cultures infected with viruses using CXCR4 showed signs of virus replication. Testing
the antigen negative cultures by PCR revealed that HIV-2 DNA was present in most
cases, whereas HIV-1 infected cultures were negative. In HIV-2 infected cultures that
were initially antigen negative but PCR positive, virus replication could in some cases
be detected several weeks later. Although preliminary, these results suggest that even if
the main coreceptors are CCR5 and CXCR4, in the absence of CCR5 the multitropic
HIV-2 may utilize, albeit less efficiently, other receptors for cell entry.
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Conclusions
Viral biological phenotype is a key player in HIV-1 pathogenesis. Initially,
biological phenotype has been defined by replication rate and cytopathology in primary
cells and cell lines, but can today be translated into molecular terms, such as usage of
different coreceptors at cell entry. CXCR4 usage determines the biological phenotype
for viruses of A, B, D and E genetic subtypes and is often associated with AIDS. The
fact that the change in virus biological phenotype may occur in the same individual
over time and is associated with progressive disease has suggested that CXCR4 using
viruses are more virulent. It is tempting to speculate that increased virulence following
entry by the CXCR4 receptor is due to differences in receptor-mediated signalling. It
remains to be seen whether signalling – if it occurs at all following HIV attachment
through the CXCR4 receptor may cause a more severe perturbance of immune
functions than signalling through the CCR5 receptor, explaining the differences
between viruses using different receptors.
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